Clinical Scorecard: In Memoriam: A Tribute to Dr. Diane E. Griffin, MD, PhD

At a Glance

Key Highlights

• Pioneering research on alphavirus and measles virus pathogenesis, revealing immune mechanisms of viral clearance and immunosuppression.
• Challenged the concept of measles as an acute infection by demonstrating prolonged viral RNA persistence and associated immunosuppression.
• Led the establishment of the Johns Hopkins Malaria Research Institute, advancing global infectious disease research.

Guideline-Based Recommendations

Diagnosis

• Consider detection of measles virus RNA in body fluids beyond rash onset to assess persistent infection.
• Evaluate immune status post-measles infection due to potential immunosuppression increasing secondary infection risk.

Management

• Monitor and manage secondary bacterial infections in children recovering from measles due to transient immunosuppression.
• Support development and use of novel measles vaccine strategies including DNA, virus-vectored, and aerosolized vaccines.

Monitoring & Follow-up

• Assess antibody repertoire diversity and abundance following measles infection to evaluate immune competence.
• Longitudinal monitoring of immune responses in patients with alphavirus encephalitis to understand disease progression.

Risks

• Increased risk of secondary bacterial infections following measles due to immunosuppression.
• Potential for fatal encephalitis from alphavirus infections influenced by host immune responses.

Patient & Prescribing Data

Children and mammals affected by measles and alphavirus infections

Immunological understanding guides vaccine development and management of secondary infections; antibody-mediated viral clearance is critical.

Clinical Best Practices

• Incorporate immunological assessments in managing viral encephalitis and measles to tailor patient care.
• Promote vaccination strategies informed by translational research to prevent measles and related complications.
• Recognize and address the prolonged immunosuppressive effects of measles to reduce morbidity from secondary infections.

References

• Johns Hopkins Bloomberg School of Public Health - Diane E. Griffin Tribute
• National Foundation for Infectious Diseases - Maxwell Finland Award